Kodiak Sciences (KOD) Non-Current Assets (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Non-Current Assets came in at $130.7 million in Q1 2026, down 15.77% YoY from $155.2 million in Q1 2025, and down 4.37% on a QoQ basis from $136.7 million in Q4 2025.
Kodiak Sciences (KOD) Non-Current Assets (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Non-Current Assets data on file, last reported at $130.7 million in Q1 2026.
- Quarterly Non-Current Assets fell 15.77% year-over-year to $130.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $558.6 million (down 16.12% YoY) and the FY2025 annual result came in at $136.7 million, down 16.45% from the prior year.
- Non-Current Assets slipped to $130.7 million in Q1 2026, from $136.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $209.2 million in Q1 2023 to a low of $130.7 million in Q1 2026.
- A 5-year average of $171.3 million and a median of $177.0 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 66.71% — and 2025, when it declined 16.45%.
- Tracing KOD's Non-Current Assets over 5 years: stood at $180.6 million in 2022, then rose by 5.23% to $190.1 million in 2023, then decreased by 13.9% to $163.6 million in 2024, then declined by 16.45% to $136.7 million in 2025, then dropped by 4.37% to $130.7 million in 2026.
- The last three Non-Current Assets figures came in at $130.7 million (Q1 2026), $136.7 million (Q4 2025), and $142.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Kodiak Sciences | 2.60 Bn | 2.60 Bn | - | 125.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125.45 Mn |
| Mar 31, 2026 | 130.75 Mn |
| Dec 31, 2025 | 136.72 Mn |
| Sep 30, 2025 | 142.34 Mn |
| Jun 30, 2025 | 148.81 Mn |
| Mar 31, 2025 | 155.22 Mn |
| Dec 31, 2024 | 163.64 Mn |
| Sep 30, 2024 | 170.18 Mn |
| Jun 30, 2024 | 176.95 Mn |
| Mar 31, 2024 | 183.25 Mn |
| Dec 31, 2023 | 190.06 Mn |
| Sep 30, 2023 | 196.73 Mn |
| Jun 30, 2023 | 202.70 Mn |
| Mar 31, 2023 | 209.22 Mn |
| Dec 31, 2022 | 180.62 Mn |
| Sep 30, 2022 | 179.33 Mn |
| Jun 30, 2022 | 177.54 Mn |
| Mar 31, 2022 | 168.10 Mn |
| Dec 31, 2021 | 169.41 Mn |
| Sep 30, 2021 | 152.70 Mn |